Breast Cancer

SWOG S2010

A Randomized Phase III Trial Comparing Active Symptom Monitoring Plus Patient Education Versus Patient Education Alone To Improve Persistence With Endocrine Therapy In Young Women With Stage I-III Breast Cancer (ASPEN)

URCC 19075 MBMC ONLY

Multi-Center Randomized Controlled Phase II Trial of Exercise to Treat Chemotherapy-Induced Peripheral Neuropathy (CIPN)

NRG BR007 Effective 4/24/23, the HRQOL sub-study has met it’s accrual goal and is closed

A Phase III Clinical Trial Evaluating De-Escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER2-Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)

URCC-21038

Disparities in REsults of Immune Checkpoint Inhibitor Treatment (DiRECT): A Prospective Cohort Study of Cancer Survivors Treated with anti-PD-1/anti-PD-L1 Immunotherapy in a Community Oncology Setting

S2013: I-CHECKIT Upcoming Temporary Closure 5/6/24 @ 2pm CST

Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective Observational Study

A011801

The COMPASSHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer): COMPASSHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared with T-DM1 and Tucatinib

A191901 ACCRUAL FOR NON-BLACK WOMEN < 50 YEARS OLD WILL CLOSE 4/15/22 *ACCRUAL FOR NON-BLACK WOMEN ≥ 50 YEARS OLD WILL CLOSE 02/25/2022

Optimizing Endocrine Therapy Through Motivational Interviewing and Text Interventions

Clinical Trials

Quick Links